KRAS and cancer: Activating mutations of KRAS are detected in more than 90% of patients with PDAC, and overexpression of KRAS and activation of the RAS/MAPK pathway are frequently observed in TNBC;13, 14 these major oncogenic activities represent potential molecular targets in these cancers.17, 18, 19 Although molecular findings provide a strong rationale for developing novel therapeutic treatments targeting KRAS, direct inhibition of KRAS has proven to be very challenging,20 leading KRAS to be classified as an undruggable target.34